Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase EARLY_PHASE1 4Phase NA 3Phase 2 3Phase 1/2 2Phase 4 1

Status

Completed 2Recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 14Thoracic 13Genitourinary 10Breast 10Lymphoid 9Endocrine 7Sarcoma 5Gynecologic 4Tumor-Agnostic 3NET 3Head & Neck 3CNS 3Other solid neoplasm 2Other hematologic neoplasm 2Dermatologic 2Plasma cell 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Oligodendroglioma 1Mesothelioma 1Medulloblastoma 1Glioblastoma 1Familial ependymoma 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1

Interventions

Temozolomide 258Radiotherapy 147Bevacizumab 142Etoposide 68Cyclophosphamide 68Carboplatin 66Magnetic Resonance Spectroscopy 58Irinotecan 53Cisplatin 52Vincristine 45Filgrastim 43pembrolizumab 40Radiosurgery 36Nivolumab 36Radiation 34Topotecan 31Doxorubicin 30Specimen Handling 29sargramostim 28Lomustine 27Erlotinib Hydrochloride 27Peripheral Blood Stem Cell Transplantation 25Carmustine 25Thiotepa 24Everolimus 23Chemotherapy, Adjuvant 23Surgical Procedures, Operative 22Isotretinoin 22Ipilimumab 22Melphalan 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Fluorodeoxyglucose F18 × CNS × Clear all
NCT06503146 2026-05-19

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
320 enrolled
CNSEndocrineGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Ovarian Neoplasms, Paraganglioma, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

NCT03732352 2024-11-12

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Jonsson Comprehensive Cancer Center

Phase 2 Completed
12 enrolled
CNS

Glioblastoma

NCT00381797 2017-11-28

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

National Cancer Institute (NCI)

Phase 2 Completed
97 enrolled 35 charts
CNS

Familial ependymoma, Medulloblastoma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡